<SEC-DOCUMENT>0001564590-22-012067.txt : 20220329
<SEC-HEADER>0001564590-22-012067.hdr.sgml : 20220329
<ACCEPTANCE-DATETIME>20220329081011
ACCESSION NUMBER:		0001564590-22-012067
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220329
FILED AS OF DATE:		20220329
DATE AS OF CHANGE:		20220329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pharvaris N.V.
		CENTRAL INDEX KEY:			0001830487
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40010
		FILM NUMBER:		22777482

	BUSINESS ADDRESS:	
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			00000
		BUSINESS PHONE:		31 (0)71 203 6410

	MAIL ADDRESS:	
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pharvaris, B.V.
		DATE OF NAME CHANGE:	20201029
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>phvs-6k_20220329.htm
<DESCRIPTION>6-K - FY 2021 PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
phvs-6k_20220329.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;border-top:Double 3pt;padding-top:1pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:18pt;font-family:Roboto Condensed;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:18pt;font-family:Roboto Condensed;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-top:0pt;margin-left:30.77%;margin-right:30.77%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:18pt;font-family:Roboto Condensed;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">FORM 6-K</p>
<p style="margin-bottom:10pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-top:0pt;margin-left:30.77%;margin-right:30.77%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER<br />PURSUANT TO RULE 13A-16 OR 15D-16 UNDER<br />THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the month of March 2022<br /><br />Commission File Number: 001-40010</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-top:0pt;margin-left:30.77%;margin-right:30.77%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:24pt;font-family:Roboto Condensed;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Pharvaris N.V.</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Translation of registrant&#8217;s name into English)</p>
<p style="margin-bottom:10pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-top:0pt;margin-left:30.77%;margin-right:30.77%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">J.H. Oortweg 21</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2333 CH Leiden<br />The Netherlands<br /><font style="font-weight:normal;">(Address of principal executive office)</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form 20-F&nbsp;&nbsp;<font style="font-family:Segoe UI Symbol;">&#9746;</font><font style="margin-left:103pt;">Form 40-F </font><font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="font-family:MS Gothic;">&#9746;</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</p>
<p style="border-bottom:Double 3pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PHARVARIS N.V.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 29, 2022, Pharvaris N.V. issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="margin-bottom:0pt;margin-top:2pt;text-align:center;text-indent:0%;font-family:Roboto Condensed;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:25.45pt;">
<td valign="bottom"  style="width:9%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:1.5pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="phvs-ex991_6.htm"><font style="text-decoration:underline;">Press Release, dated March 29, 2022</font><font style="text-decoration:underline;font-family:Times New Roman;">.</font></a></p></td>
</tr>
<tr style="height:7.8pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:7.8pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.7pt;">
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PHARVARIS N.V.</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 29, 2022</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:43.58%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Berndt Modig</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:43.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Berndt Modig</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:43.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Roboto Condensed;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>phvs-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
phvs-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdxf0aigkvzp000001.jpg" title="" alt="" style="width:224px;height:32px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Roboto Condensed;font-style:normal;text-transform:none;font-variant: normal;">Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Phase 1 pharmacokinetics study demonstrates PHVS719 well tolerated with extended-release profile supporting once-daily dosing </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Orphan Drug Designation for PHA121 granted by FDA </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks ongoing; top-line data anticipated in 4Q22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks trial enrolling patients; top-line data anticipated in 4Q22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Executing from a strong financial position with cash and cash equivalents balance of &#8364;209.4 million as of December 31, 2021; runway expected into 1Q24</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Zug, Switzerland, March 29, 2022<font style="font-weight:normal;"> &#8211; </font><font style="text-decoration:underline;font-weight:normal;">Pharvaris</font><font style="font-weight:normal;"> (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided recent business highlights. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;The time since our initial public offering in February 2021 has been transformational for Pharvaris, enabling us to reach clinical development milestones, including initiation and continued progress of our Phase 2 RAPIDe-1 on-demand study of PHVS416, the initiation and enrollment of our Phase 2 CHAPTER-1 prophylactic study of PHVS416, and the completion of our Phase 1 pharmacokinetics study for PHVS719,&#8221; said Berndt Modig, chief executive officer of Pharvaris. &#8220;We look forward to our next milestones, including announcing top-line data from our Phase 2 trials, RAPIDe-1 and CHAPTER-1. We will continue to execute our strategy efficiently in 2022 supporting our mission to provide individual choice for managing HAE through potent and convenient oral on-demand and prophylactic therapies.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Business Highlights and Updates</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Pipeline</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><a name="_Hlk99095390"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Top-line Phase 1 data demonstrate extended-release PHVS719 suitable for once-daily dosing. </font><font style="color:#000000;">The Phase 1 pharmacokinetics (PK) study of PHVS719 included 8 healthy volunteers dosed in an open-label </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="color:#000000;">randomized five-period crossover single-dose study to assess bioavailability of two different extended-release formulations with and without food, in comparison to a single dose of PHVS416 without food. The pharmacokinetics of a single dose of PHVS719 </font><font style="color:#000000;">(40 mg) </font><font style="color:#000000;">under fasted conditions yielded exposure above 13.8 ng/mL</font><font style="color:#000000;"> (the EC</font><font style="color:#000000;"><sub style="font-size:85%; vertical-align:bottom">85</sub></font><font style="color:#000000;"> determined in a Phase 1 bradykinin challenge in healthy volunteers)</font><font style="color:#000000;"> by the two-hour timepoint and maintained this exposure for at least an additional 28 hours.</font><font style="color:#000000;"><a name="_Hlk99095390"></a> </font><font style="color:#000000;">The overall exposure was not affected by food</font><font style="color:#000000;">. </font><font style="color:#000000;">The 24-hour area</font><font style="color:#000000;">-</font><font style="color:#000000;">under</font><font style="color:#000000;">-</font><font style="color:#000000;">the</font><font style="color:#000000;">-</font><font style="color:#000000;">curve (AUC</font><font style="color:#000000;"><sub style="font-size:85%; vertical-align:bottom">24h</sub></font><font style="color:#000000;">) exposure of PHA121 using PHVS719 </font><font style="color:#000000;">(40 mg) </font><font style="color:#000000;">is similar to that observed in Phase 1 studies with PHVS416 softgel capsules dosed 20 mg twice a day with food </font><font style="color:#000000;">(</font><font style="color:#000000;">one of the doses used in the CHAPTER-1 prophylactic proof-of-concept study</font><font style="color:#000000;">)</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font><font style="color:#000000;">The study showed </font><font style="color:#000000;">that </font><font style="color:#000000;">PHVS416 and PHVS719 were well tolerated. During the study, there were no </font><font style="color:#000000;">severe adverse events (</font><font style="color:#000000;">SAEs</font><font style="color:#000000;">)</font><font style="color:#000000;"> or severe treatment-emergent adverse events</font><font style="color:#000000;"> (</font><font style="color:#000000;">TEAEs</font><font style="color:#000000;">)</font><font style="color:#000000;"> reported.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are thrilled to have achieved with the PHVS719 extended-release formulation for the first time the possibility of a once-daily oral bradykinin receptor antagonist for prevention of hereditary angioedema attacks,&#8221; said Jochen Knolle, CSO of Pharvaris. &#8220;The versatile properties of PHA121, in this case the ability to be absorbed through the colon, combined with the appropriate slow-release technologies, has enabled a release profile well-suited to all-day exposure of compound. This single-dose study showed that PHVS719 (40 mg) maintained PHA121 exposure for a full day above the levels that prevented the effects of a surge of bradykinin as shown in our mechanistic study in healthy volunteers. We look forward to confirming these results in an upcoming multi-dose PK study, to support use of PHVS719 in a future pivotal clinical study when combined with the anticipated results of our CHAPTER-1 proof-of-concept study.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Orphan Drug Designation granted by FDA. </font><font style="color:#000000;">On March 18, 2022, the FDA granted orphan drug designation to PHA121, the active ingredient in our PHVS416 and PHVS719 product candidates, for treatment of bradykinin-mediated angioedema.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Phase 2 on-demand study (RAPIDe-1) of PHVS416 ongoing. </font><font style="color:#000000;">RAPIDe-1, a Phase 2 clinical study of PHVS416 for the on-demand treatment of HAE attacks, continues enrollment and attack surveillance across 33 clinical sites in Canada, Europe, Israel, the UK and the U.S. Top-line data from the study is anticipated to be available in the fourth quarter of 2022. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Phase 2 prophylactic study (HAE CHAPTER-1) of PHVS416 enrollment ongoing. </font><font style="color:#000000;">CHAPTER-1, a Phase 2 clinical trial of PHVS416 for the prophylactic treatment of HAE attacks, is enrolling patients across clinical sites in Canada, Europe, Israel, the UK and the U.S. Top-line data from the study is anticipated to be available in the fourth quarter of 2022. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">RAPIDe-2 expected to initiate in 2022. </font><font style="color:#000000;">RAPIDe-2, an open-label extension study evaluating PHVS416 for the on-demand treatment of people with HAE, is expected to initiate in the second half of 2022. </font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdxf0aigkvzp000002.jpg" title="" alt="" style="width:175px;height:25px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Preclinical data of PHA121 published in </font><font style="font-weight:bold;font-style:italic;color:#000000;">International Immunopharmacology.</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">In March 2022, Pharvaris announced the publication of preclinical data in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">International Immunopharmacology</font><font style="color:#000000;"> demonstrating the specificity and potency of PHA121, the active ingredient in our PHVS416 and PHVS719 product candidates. </font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.14%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Corporate </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><a name="_Hlk99036533"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Board of Directors. </font><font style="color:#000000;">In December 2021, Pharvaris announced the appointments of Elisabeth Bj&#246;rk, M.D.,<a name="_Hlk99036533"></a> and Anne Marie de Jonge Schuermans, Ph.D.,</font><font style="font-size:9pt;font-family:Segoe UI;color:#000000;"> </font><font style="color:#000000;">to the board of directors with expected confirmation at the company&#8217;s upcoming 2022 annual general meeting of shareholders. Dr. Bj&#246;rk and Dr. de Jonge Schuermans have replaced Martijn Kleijwegt and R&#233;mi Droller, both of whom stepped down from the board in December 2021 to focus on new investments. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Year End 2021 Financial Results</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Liquidity Position. </font><font style="color:#000000;">Cash and cash equivalents were &#8364;209.4 million as of December 31, 2021, compared to &#8364;98.6 million for December 31, 2020. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Research and Development (R&amp;D) Expenses. </font><font style="color:#000000;">R&amp;D expenses were &#8364;10.7 million for the fourth quarter and &#8364;35.8 million for the full year of 2021, compared to &#8364;7.7 million for the fourth quarter and &#8364;19.5 million for the full year of 2020.</font><font style="font-weight:bold;color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">General and Administrative (G&amp;A) Expenses</font><font style="color:#000000;">. G&amp;A expenses were &#8364;5.5 million for the fourth quarter and &#8364;18.3 million for the full year of 2021, compared to &#8364;2.1 million for the fourth quarter and &#8364;5.5 million for the full year of 2020. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Roboto Condensed;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Loss for the year. </font><font style="color:#000000;">Loss for the fourth quarter was &#8364;12.3 million, resulting in basic and diluted loss per share of &#8364;0.41. For the full year, loss was &#8364;42.7 million, resulting in basic and diluted loss per share of &#8364;1.40 per share. This compares to &#8364;10.6 million, or basic and diluted loss per share of &#8364;2.18, for the fourth quarter and &#8364;26.0 million, or basic and diluted loss per share of &#8364;5.36, for the full year of 2020.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Note on International Financial Reporting Standards (IFRS)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. Pharvaris maintains its books and records in the Euro currency.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About RAPIDe-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RAPIDe-1 study is a clinical research study for people who have been diagnosed with HAE. The main purpose of the study is to find out how effective three different doses of the study drug, PHVS416, are in relieving </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdxf0aigkvzp000002.jpg" title="" alt="" style="width:175px;height:25px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">symptoms associated with HAE attacks. Researchers developed the study drug in the form of soft</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gel</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> capsules which are taken orally and could be a more convenient alternative to an injection into a vein or under the skin for resolving HAE attacks. For more information, visit </font><font style="text-decoration:underline;">https://hae-rapide.com/</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">https://hae-rapide.us/</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </font><font style="text-decoration:underline;">https://clinicaltrials.gov/ct2/show/NCT04618211</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About HAE CHAPTER-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The HAE CHAPTER-1 study is a clinical research study for people who have been diagnosed with HAE. The main purpose of the study is to evaluate two different doses of the study drug, PHVS416, in preventing HAE attacks. Researchers developed the study drug in the form of softgel capsules which are taken orally and could be a more convenient alternative to an injection into a vein or under the skin for preventing HAE attacks. For more information, visit <font style="text-decoration:underline;">https://haechapter-1.com</font> or <font style="text-decoration:underline;">https://clinicaltrials.gov/show/NCT05047185</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About PHVS416</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHVS416 is a softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor. Pharvaris is developing this formulation to provide fast and reliable symptom relief when patients want, through rapid exposure of attack-mitigating medicine in a convenient, small oral dosage form. PHVS416 is currently in Phase 2 clinical development for the on-demand treatment of HAE.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About PHVS719</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHVS719 is an extended-release tablet formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor. Pharvaris is developing this formulation to provide an easy way to prevent attacks with sustained exposure of attack-preventing medicine in a convenient, small oral dosage form. PHVS719 is currently in Phase 1 clinical development for the prophylactic treatment of HAE.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About PHA121</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHA121 (PHA-022121) is a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor that has completed Phase 1 clinical development for the treatment of HAE. PHA121 utilizes the same mechanism as icatibant, the leading therapy for on-demand treatment of HAE. Pharvaris is developing this novel small molecule for on-demand and prophylactic treatment of HAE and other bradykinin-mediated diseases through formulations optimized for each setting. Data from single- and multiple-ascending-dose Phase 1 studies in healthy volunteers demonstrate rapid exposure and linear pharmacokinetics at doses up to 50 mg. In a bradykinin-challenge study in healthy volunteers, PHA121 showed significant inhibition of </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdxf0aigkvzp000002.jpg" title="" alt="" style="width:175px;height:25px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bradykinin-induced hemodynamic changes with an average composite EC</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">50</sub></font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of 2.4 ng/mL and EC</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">85</sub></font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of 13.8 ng/mL, approximately four-fold more potent than historical data for icatibant. Quantitative modeling indicates that single oral doses of PHA121 will maintain pharmacological effectiveness for a substantially longer time than 30 mg of subcutaneous icatibant. PHA121 has been observed to be well-tolerated at all doses studied to date.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Pharvaris</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit <font style="text-decoration:underline;">https://pharvaris.com/</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements containing the words &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;will,&#8221; &#8220;intend&#8221; and similar expressions. These forward-looking statements are based on management&#8217;s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris&#8217; actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: the expected timing, progress, or success of our clinical development programs, especially for PHVS416 and PHVS719, which are in early-stage clinical trials; risks associated with the COVID-19 pandemic, which may adversely impact our business, preclinical studies, and clinical trials; the timing of regulatory approvals; the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates PHVS416 and PHVS719, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws, our ability to </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdxf0aigkvzp000002.jpg" title="" alt="" style="width:175px;height:25px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully remediate the material weakness in our internal control over financial reporting and to maintain an effective system of internal control over financial reporting; </font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changes in general market, political and economic conditions, including as a result of the current conflict between Russia and Ukraine</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the other factors described under the heading</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; and</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3. Key Information</font><font style="font-size:9pt;font-family:Arial;">&#8212;</font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D. </font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors&#8221; in our </font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report </font><font style="font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on Form 20-F and other periodic filings with the Securities and Exchange Commission. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management&#8217;s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris&#8217; views as of any date subsequent to the date of this press release. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Contacts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Pharvaris<br /><font style="font-weight:normal;">Maryann Cimino<br />Director of Corporate Relations<br />+1-617-710-7305<br /></font><font style="text-decoration:underline;font-weight:normal;">maryann.cimino@pharvaris.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sarah McCabe</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">sarah.mccabe@sternir.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1-212-362-1200</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Roboto Condensed;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Media </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maggie Beller, Russo Partners, LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">maggie.beller@russopartnersllc.com</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1-646-942-5631</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Roboto Condensed;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdxf0aigkvzp000002.jpg" title="" alt="" style="width:175px;height:25px;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gdxf0aigkvzp000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdxf0aigkvzp000002.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[@ .061O8F4 9      "_]L 0P # @(#
M @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3
M%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  % @
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MBOS+^U\=_P _/P7^1_:O^H/#7_0(O_ I_P#R1^J=%%%>4?\ "A8/^@S)_P"
MX_\ BJ/^%"P?]!F3_P !Q_\ %5ZO11_:^._Y^?@O\@_U!X:_Z!%_X%/_ .2"
MBBBO*/\ A0L'_09D_P# <?\ Q5'_  H6#_H,R?\ @./_ (JO5Z*/[7QW_/S\
M%_D'^H/#7_0(O_ I_P#R04445Y1_PH6#_H,R?^ X_P#BJ/\ A0L'_09D_P#
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M_ <?_%4?\*%@_P"@S)_X#C_XJO5Z*/[7QW_/S\%_D'^H/#7_ $"+_P "G_\
M)!1117E'_"A8/^@S)_X#C_XJH)O@&W)BUL'T#VN/UWUZ]10LXQR_Y>?@O\B)
M>'_#4E;ZK_Y//_Y(****\%U#X*^(+16: VMZ >%BEVL?^^@!^M<CJWA[4]"D
MVW]C/:\[0TB':3[-T/X&OJBFR1I-&R2*KHPP589!'H17H4<_KQ?[V*DON?\
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M?]!F3_P''_Q5'_"A8/\ H,R?^ X_^*KU>BOC_P"U\=_S\_!?Y']"?Z@\-?\
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M]6QU/GAR2=KM:JW9IA11161_PH6#_H,R?^ X_P#BJ/\ A0L'_09D_P# <?\
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M"\\X9S/AZIRXVG[KVDM8OT?3T=GY!11156BBBN\^5"BBBBBBB@ HHHHHHHH
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M\_D?G/'7#L<^RR4J4?WU*\H]WWC\UMYV"BBBOG"BBBOTL_C *****[/X0?\
M(]V7^Y+_ .@&N,KL_A!_R/=E_N2_^@&N''_[K5_PO\CZ?A?_ )'N"_Z^0_\
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M),56>(K3JOJ_^&/[XR7+HY3EU# Q^Q%)^;ZOYN["BBBBBBBN8]D********
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M$Y/XUI445^1RDYR<I;L_ONA1AAZ4:-)6C%))=DM$%%%%%%%%2;!11111110
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M,>IN<FK6V\[GY;QMQ=B>%Y8=8>E&?M.:][Z<O+V]0HHHKZ9_X3WP[_T&;/\
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M1794445^;']D!11111110 44444444 %%%%%%%% !11117SK\5-$_L7QE=[
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M1179_"#_ )'NR_W)?_0#7&5V?P@_Y'NR_P!R7_T UZF/_P!UJ_X7^1\3PO\
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MHK\O/[<"BBBBBBB@ HHHHHHHH ****\1^.W_ ",6G_\ 7K_[.U>:UZ5\=O\
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MKM>R2]>5*_9Z!11111117C'Z*%%%%%%%% !11117E'Q[EVVNC1[B-SRMM['
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M_P K!11111117L'YZ%%%%%%%% !11115S1M,DUK5K2QBR'N)5C# 9VY/)QZ
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M "BBBBOGCXN2!O'NH =56('_ +]J?ZU]#U\T?$*^&H>-M8E P!.8O^^ $_\
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MK^^-U\PHHHKYWHHHK]//XF"BBBBBBB@ HHHHHHHH *****]*^!/_ ",6H?\
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M1**X\1G.*Q$7#2*?8^@RCP\R3*:ZQ*4JDXZKG::3[I))??<********\,_3
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MZ17U#7C_ ,=M#VS:?JZ X8?99.>,C+)_[/\ D*^CR+$>RQ/LWM+\UM^I^/\
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M^([Z<+/;QV$7>2:53^04DY_*O6?!?@"P\&0NT1-S>R#$ES( #C^ZH_A7//\
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MV7_HI*^BJ^=?BQ_R4#5?^V7_ **2OIN'_P#>I?X7^:/Q?Q7_ .1)1_Z^Q_\
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M3^%^)LEGD&:5<$_A3O%]XO;_ "?FF%%%%%%%%=Y\L%%%%%%%% !11111110
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MOT?)/]RCZO\ ,_CSQ*_Y**K_ (8?D%%%%%%%%>\?EH44444444 %%%%%%%%
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MQN?^N;?R-?)]?:<._#5^7ZG\X>+OQX'TJ?\ M@44444445]B?SR%%%%%%%%
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M%%%%% !11111110 44444444 %%%%%%%% !11145S<1V=O+/,XCAB0N['H%
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MPN#K8B#G35U<^0SCB3+<GKQH8RIRR:O;RNU^C"BBBMFBBBO+/KPHHHHHHHH
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M110,******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH
M******** "BBBBBBB@ HHHK-\1:.FO:'?:>^W_2(BJEAD*W53^!P?PKY;EB>
M"5XY$9)$8JRL,$$<$&OK:OGGXLZ$-%\87$B+M@O!]I7KC<?OC/KN!/XBOK>'
M\1RSG0?75?K_ %Y'X'XKY5[7#4,T@M8/DEZ/5?<[K_MX****XVBBBON#^9@H
MHHHKTKX$_P#(Q:A_UZ_^SK7FM>E? G_D8M0_Z]?_ &=:\K-/]RJ>GZGW/ __
M "46#_Q?HPHHHKVZBBBOR\_MP******** "BBBBBBB@ HHHKQ'X[?\C%I_\
MUZ_^SM7FM>E?';_D8M/_ .O7_P!G:O-:_4<K_P!SI^A_$?''_)18S_$O_24%
M%%%%%%%>H?#!1117LWP0\3?:+&XT29OGM\S0?[A/S#IV8YZ_Q>U>I5\M>&=<
MD\.:]9ZA'G]S("ZK_$AX9?Q!-?4%K<Q7EM%<0N)(94#HZ]&4C(-?GF=X7V.(
M]K%:3_/K_F?UOX:YY_:65?4JKO4H:>L'\/W:Q]$NX4445+1117SI^O!11111
M110 444457U"QAU.QN+2X7?!.C1NOJ",&K%%--Q=T3.$:D7":NGHT%%%%?*_
MB#19O#NM7>G3\O;OM#8QN7JK=>,@@_C6?7LWQN\+FZLH-;@3,EO^YN,?\\R?
ME;KV8XZ?Q>U>,U^J8#%+&8>-3KL_7^M3^&N*LCEP_FM7!V]S>#[Q>WW?"_-,
M********] ^1"BBBBBBB@ HHHHHHHH ******** "BBBBN]^#.N?V9XK^R.V
M(;Z,QXXQO'S*?_0A_P "K@JEM+J6QNH;F!MDT+K(C>C Y!_,5S8FBL11E2?5
M'LY-F4\HS&ACH?8DF_-=5\U=!1117UG1532=2CUC2[2^B!$=Q$LH!ZC(S@^X
MJW7Y)*+BW%[H_OBG4C6A&I!W35UZ,********1H%%%%%%%% !11111110 44
M444453U?4H]'TN[OIN8[>)I2!U.!G ]STIQBY-16[,ZE2%&$JE1VBE=OR044
M45XA\9M<_M/Q7]D1LPV,8CQVWGYF/_H(_P" UP52W=U+?74US.V^:9VD=O5B
M<D_F:BK];PU%8>C&DNB/X'SG,IYOF-?'3^W)M>2Z+Y*R"BBBBBBBND\8****
M**** "BBBBNU^$6A_P!K^,(9G7=#9*;ALKD;APHSV.2#_P !KBJ]W^"VAC3O
M##W[KB:^DW=\[%)51^>X_B*\?-L1]7PDFMWHOG_P+GZ%P'E7]JY[1C)7A3]^
M7_;NWWRM\@HHHKT&BBBOS(_M,******** "BBBBBBB@ HHHHHHHH *******
M* "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ****X'XS:'_
M &EX4^V(N9K&02<+D[&^5A_Z"?\ @->"U]8WUG%J%G/:SKNAGC:-U]5(P?T-
M?+&J:?+I.I75E-_K;>5HF..#@XR/8U]UD&(YJ4J#^SJO1_\ !_,_E_Q6RKV&
M.HYE!:5%RO\ Q1V?SBTO^W0HHHJK1117U9^%!11117O'P2_Y$U_^OI__ $%:
M\'KWCX)?\B:__7T__H*U\]GO^Y_-'ZYX7_\ (_\ ^W)?H%%%%>@4445^=G]<
MA11111110 44444444 %%%%?,?CK_D<M9_Z^I/\ T(UAUN>.O^1RUG_KZD_]
M"-8=?KN'_@P]%^1_ &;_ /(QQ/\ CG_Z4PHHHHHHHKH/)"BBBOI3X?\ B3_A
M*/#%K=2-NNH_W-Q_OKWZ#J,-^.*Z2O!?@[XF&C>(C8S-BWU "/)[2#.S\\D?
M4BO>J_+\SPOU3$RBE[KU7]>1_;?!>>?V[D].M-WJ0]V?JNO_ &\K/U;70***
M*****\H^Z"BBBBBBB@ HHHHKF?B)X9_X2GPS<6\:[KN']];^I<#[OXC(_$'M
M7345K2JRHU(U(;HX<=@Z.8X6IA,0KPFFG\_U6Z\PHHHKY'HKN/BYX9_L'Q,U
MU$N+34,S+[/GYQU]2&_X%CM7#U^L8>M'$4HU8;,_@W-<MK91CJN!K_%3=O5=
M'Z-6:\F%%%%%%%%=!Y044445Z5\"?^1BU#_KU_\ 9UKS6O2O@3_R,6H?]>O_
M +.M>5FG^Y5/3]3[G@?_ )*+!_XOT84445[=1117Y>?VX%%%%%%%% !11111
M110 4445YE\=O^0#IW_7S_[(:\4KVOX[?\@'3O\ KY_]D->*5^CY)_N4?5_F
M?QYXE?\ )15?\,/R"BBBBO;?@CXABNM'FTA@J7-JQD7  +QL>I]2"<?0K7B5
M:OA?Q!-X8URVU"'+>6V'CSC>A^\OY?K@UV9AA?KF'E36^Z]3Y[A+//\ 5_-J
M>+E\#]V?^%[_ ':/Y6"BBBOJ.BJ]C?0:E907=L_F03()$8=P1D58K\M:<79G
M]Q0G&I%3@[IZI]PHHHHHHHI%!11111110 44445Q7CSX:VGBY6NH&6TU15P)
M<?++CH'_ )9Z_7 %=K16]&O4P\U4I.S1YF99;A,WPTL)C8*<'^'FGT?F@HHH
MKY6UG0=0\/W1M]0M9+:7MN'#>X(X(^E4*^KM1TNSU:W,%[;174)YV2H& /J,
M]#[UPVJ_!+1+QF>SEN-/8C 56\Q ?7#<_P#CU?:8?/Z4E:NN5^6J_P _S/YQ
MS?PKQU";GE=15(=%)\LOO^%^ON^@4445X517K1^ ;YXUQ2/^O7_[.K-C\!;9
M),WFKRS)_=@A$9_,EOY5Z#SG I7Y_P '_D?)P\.^)9247AK>;G"WX2;_  "B
MBBO'HXWFD6.-6=V(5549))Z "O:/A?\ #-]'DCUC5DVWF,P6Q_Y99'WF_P!K
M';M]>G7>'? NB^%R'LK1?M &/M$QWR=,<$],^V*Z"OG,PSIXB+I4%:+W?5G[
M!PGX<PRFM''9G)3JQUC%?#%][NUVNFED]==&BBBBBBBBOES]M"BBBBBBB@ H
MHHHHHHH ****\^^-FI?9/"26H*[KJ=5*D\[5RQ(_$+^=%<7\:]<&H>)8K!#F
M.QCP>/XWP6_0+^M%?I>3T71P<;[RU^__ (%C^,?$#,5F/$%;D=XT[07_ &[O
M_P"3-A1117NM%%%?FA_9P44444444 %%%%%%%% !1115?4/^/&Y_ZYM_(U\G
MU]8:A_QXW/\ US;^1KY/K[3AWX:OR_4_G#Q=^/ ^E3_VP********^Q/YY"B
MBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBN
MS^$'_(]V7^Y+_P"@&N,KL_A!_P CW9?[DO\ Z :X<?\ [K5_PO\ (^GX7_Y'
MN"_Z^0_]*04445]"T445^4']W!11111110 44444444 %%%%>1_'W_F!?]M_
M_:=>1UZY\??^8%_VW_\ :=>1U^F9/_N-/Y_FS^+_ !#_ .2FQ7_;G_IN 444
M44445[)^=!11111110 44444444 %%%%>P_ 7_CTUG_?B_DU>KUY1\!?^/36
M?]^+^35ZO7YEF_\ OU3Y?DC^U> ?^2:PGI+_ -+D%%%%%%%%>.?H 4444444
M4 %%%%%?.OQ8_P"2@:K_ -LO_125]%5\Z_%C_DH&J_\ ;+_T4E?3</\ ^]2_
MPO\ -'XOXK_\B2C_ -?8_P#I$PHHHKD:***^_/Y2"BBBBOHGX5:+_8W@RS++
MB:[_ -*?G/WON_\ CH7]:\)\,Z,WB#7[#3U#8GE"N5(!"#EB,^B@G\*^HT58
MU55 55& !V%?(<08BT(4%UU?Z?UY'] >$^5\]?$9I-:17)'U>LOFE;_P(***
M*=1117Q)_2H44444444 %%%%%%%,DD6&-Y'8(B@LS'H .IH!M)784444^BOE
MK7->N-8UB]O3+*HGE9U4N?E4GA?P&!^%4?MD_P#SWD_[[-?7QX>DTFZEGZ?\
M$_G^MXMT85)1IX-RBF[/GM==[<NEPHHHKZSHKY,^V3_\]Y/^^S1]LG_Y[R?]
M]FJ_U=?_ #]_#_@F7_$7:?\ T!/_ ,&?_:!1117UG17R9]LG_P">\G_?9H^V
M3_\ />3_ +[-'^KK_P"?OX?\$/\ B+M/_H"?_@S_ .T"BBBOK.BODS[9/_SW
MD_[[-'VR?_GO)_WV:/\ 5U_\_?P_X(?\1=I_] 3_ /!G_P!H%%%%?6=%?+WA
MO7Y]&UZPO6GD\N&96DY)RF<,,?3-?4 (8 @Y!KQ,PR^6 E%.5T_*Q^D\)\64
MN*:56<:7LY4VDU>^C6CV79].@4444M%%%>2?>!11111110 44445YU\;=%^W
M>&X=01<R6,OS'/\ RS?"GZ_-L_6O1:JZGI\>JZ;=64V?*N(FB;'7!&,BNK"5
MWAJ\*JZ/\.OX'A9[EL<XRRO@)?;BTO7>+^3284445\HT5-?6<NGWEQ:S#;-!
M(T3@=F4X/ZBH:_6DTU='\%3C*G)PDK-!11117I7P)_Y&+4/^O7_V=:\UKTKX
M$_\ (Q:A_P!>O_LZUY>:?[E4]/U/MN!_^2BP?^+]&%%%%>W4445^7G]N!111
M11110 44444444 %%%%>(_';_D8M/_Z]?_9VKS6O2OCM_P C%I__ %Z_^SM7
MFM?J.5_[G3]#^(^./^2BQG^)?^DH********]0^&"BBBBO;_ (*^)O[0T:72
M9G!GLOFCR>6B)^O.#Q[ K7B%;7@WQ"WA?Q%9WX+>4K;9E7^*,\,,=_4>X%>9
MF.%^MX>4%NM5Z_UH?:<'YV\AS>EB9.U.7NS_ ,+Z_)VE\@HHHKZ>HIL<BR1J
MZ$,C#(8="/6G5^6G]P[ZH******** "BBBBBBB@ HHHJ&\M(K^TFMIT\R&9#
M&ZGNI&"*^7_$FAR^&]<N].FY,+X5O[RGE6_$$5]35YG\:O"POM,CUF!,W%KA
M)L=XB>#^!/Y$^E?19+B_85_92^&?Y]/\C\C\2,A_M3*_KM%?O*%WZP^TOE\7
MR?<****\3HHHK]#/Y&"BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHK
MW'X(ZY]M\.SZ<Y_>64F5&/X'R1_X]N_,5Z/7SK\*];_L7QE9[CB&ZS:OQG[V
M-O\ X\%_#-?15?FV<X?V&+<EM+7_ #_$_L?P[S7^TLBITY/WZ/N/T7P_^2M+
MY,********\,_3@HHHHHHHH ******** "BBBBO-_C=KGV+P_;Z:A^>]DRW'
M\"8/_H6W\C7I%?.GQ3UO^VO&5YM;=#:XMDX_NYW?^/%OTKW<FP_M\4I/:.O^
M7XGYCXB9M_9N15*<'[]9\B]'K+_R5-?-!1117)4445^D'\<!11111110 444
M44444 %%%%3V%G)J5];6D./.N)%B3=TW,0!_.OJG3[&/3;"VM(1B&"-8D^BC
M _E7B'P5T/\ M'Q.]\X_=6$>X?[[950?PW'Z@5[O7P>?XCGK1HK[/YO_ ('Y
MG]2>%65?5\OJYC-:U79?X8_YRNO^W0HHHHHHHKY8_<0HHHHHHHH *******Y
MSXA:R="\'ZC<(Q69H_)C(;:0SG;D'U&2?PK2E3=:I&G'=NQQXW%T\#A:N+J_
M#"+D_1*X4445T=%?)GVR?_GO)_WV:/MD_P#SWD_[[-?6_P"KK_Y^_A_P3\&_
MXB[3_P"@)_\ @S_[0****^LZ*^3/MD__ #WD_P"^S1]LG_Y[R?\ ?9H_U=?_
M #]_#_@A_P 1=I_] 3_\&?\ V@4445]9T5\F?;)_^>\G_?9H^V3_ //>3_OL
MT?ZNO_G[^'_!#_B+M/\ Z G_ .#/_M HHHKZSHKY,^V3_P#/>3_OLT?;)_\
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M%%%5]0_X\;G_ *YM_(U\GU]8:A_QXW/_ %S;^1KY/K[3AWX:OR_4_G#Q=^/
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MHHHHHH ******** "BBBE5FC8,I*LIR"#@@U]1>%M:7Q%X>L-0!&Z:(%PH(
M<<,/P8&OERO8O@7KGF6E_I,C?-&PN(@3SM. P'L#M_[ZKYO/</[7#JJMXO\
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MLNT'&[!R1GWZ?C7U3%(LT:2(P9' 96'0@]#7R57T5\*]8_MCP799;,MKFU?
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M4]_@?_DHL'_B_1A1117MU%%%?EY_;@44444444 %%%%%%%% !1117F7QV_Y
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M* "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHKL_A!_R/=E_N2_\
MH!KC*T?#^O77AO5(K^SV>?&& \Q<KR"#Q^-<V*IRK4)TX[M-'M9)C*>7YGAL
M76^&$XR=M[)IL****^IZ*\$_X77XB]+/_OR?\:/^%U^(O2S_ ._)_P :^$_L
M+%^7WG]0?\10R#^__P" _P#!"BBBO>Z*\$_X77XB]+/_ +\G_&C_ (77XB]+
M/_OR?\:/["Q?E]X?\10R#^__ . _\$****][HKP3_A=?B+TL_P#OR?\ &C_A
M=?B+TL_^_)_QH_L+%^7WA_Q%#(/[_P#X#_P0HHHK?^/O_,"_[;_^TZ\CK?\
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M4445[W17@G_"Z_$7I9_]^3_C1_PNOQ%Z6?\ WY/^-+^PL7Y?>'_$4,@_O_\
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MBO!/^%U^(O2S_P"_)_QH_P"%U^(O2S_[\G_&OD?["Q?E]Y^__P#$4,@_O_\
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M=%>"?\+K\1>EG_WY/^-'_"Z_$7I9_P#?D_XT?V%B_+[P_P"(H9!_?_\  ?\
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-D"BBBBBBB@ HHHK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gdxf0aigkvzp000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdxf0aigkvzp000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !E KT# 2(  A$! Q$!_\0
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MYS>E2\6?$JG3IYGCZ=.G#CGB>$*<(8JK&$(1CF:C&,8QC&,4DHI))61^A_\
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MWG_O_,\J+9^+_P#P];_;Y_Z+P?\ PVOPD_\ F$K]&?\ @O?]W]E__KI\6O\
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M\.R_"[7H/#OQ4^(?C&UT;PYJ<FEZ1K,FF:#HD/\ :_BO4XM.UVQU+2YV\O\
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M.?\ H@>"_P#Q%\D_^83\(_XC?XT?]'<\3?\ Q.^*/_GIY+[C]#_^'K?[?/\
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MVF:?%-KGBC4XM-URRU'2[@)8V=OH[-=6-RL$FNPRQK'.L4L?Z5U_*!_P6O\
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M6\OO#,2:7XCU<ZIX@\,:OJ$ZZAXB@U1K8?:S;I8QV@AC7YF;YB_X>M_M\_\
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MJ>&]9TCQ%H=U)8ZUX?U73M<T>]B)66SU72+R'4-.NHV[/;WEO#*I]4%?WQ_
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M=5TJM+^V3 ]!^5&!Z#\J6OS]_P""AG[;.E_L<_">.ZT9;'5OC!X\^W:5\-M
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M=)\ ^$=<\3W$<C[/M<FEV$UQ9Z=&W4W&J7JVVG6J#YI+FZB1?F85Z57XE_\
M!;SXX?\ "'? ;P;\$]+O?*UCXP>)UU+7((I<2?\ "$^!9+74[B.>-?F$6H^*
M+GPXL18A9DTZ^CVN%?;]EX>\+U.-.->'.&HQDZ69YG0AC'"ZE3RVA?%9E536
MTJ> H8B<'=7FHJZ;1^9^,G'M'PQ\+^->.*DH1K9%D>*J9;&I;DK9UB^7 9)A
MY*7Q1KYMBL'3J)*35.4Y<LK6/Y?_ !/XDUCQEXE\1>+_ !#<O>Z_XKUW5_$F
MMWDA+/=:OKNH7&J:C.Q.2?-O+J9QR< @=!6'117^P=.G3HTZ=&E"-.E2A&G3
MIP2C"%.$5&$(Q6D8QBE&*6B221_S85Z];$UZV)Q%2=:OB*M2O6JU)2G4JU:L
MW4J5*DY-RG.<Y2E*4FY2DVVVV%?47[%OQM?]GK]I[X0_%":Y:VT/3?%%MHGB
M]@?D;P;XI5O#WB1Y5/RR+8V&H/JT2MP+K3K>0%616'R[2, P*GHP(/T(P:XL
MWRS"YWE699/CH>TP6:X'%Y=BX:>]A\90GAZR5TTI<E27*^DK-:H]7AO/LPX6
MXAR/B7*:KH9GP_F^79SE]77W,9EN+I8S#N233<?:T8J<;I2@W%Z-G^B>CK(B
MR1LKHZJZ.A#(Z, RLK*2&5@058$@@@@XIU?#7_!./XX-\>OV0_A3XFOKS[9X
MF\+Z8WPW\8NS;YCK_@A8M*2ZN6ZM<:QH8T7797(!9]48\_>/W+7^-V?Y-B^'
M<[S;(<=&V,R?,<9EV(T:C*IA*\Z#J0OO3J\GM*<M5*G*,DVFF?\ 3)PAQ-E_
M&?"O#O%N52YLNXDR7+<ZPFJE*%',<)2Q4:-2VU:@ZCHUH-*4*U.<))2BTBBB
MBO(/HC^6+_@NI_R<O\*?^R'6/_J>>-*_$ROVS_X+J?\ )R_PI_[(=8_^IYXT
MK\3*_P!8/ S_ )-+P/\ ]BF?_J;BS_GG^EC_ ,I$^*?_ &4%/_U5Y>%3);7,
MJ[XK:YE0D@/%;S2(2.H#(C+D=QG([U#7]=__  1ML;&X_8C\-R7%E:3R?\+"
M^(XWS6T,CD#7> 7="QQT&3P  . *[/%?Q%_XACPQ2XC_ +(_MKVF:X3+/J?U
M[^S[?6J.+K>V]O\ 5,;?D^J\OL_8KFY^;G7+:7F_1Y\%?^(\<=XG@I\1_P"J
M_P!7X?Q^>_VC_97]L<_U+%9?AOJWU3^T<LY?:?7N?VWUA\GLN7V4N>\?Y&39
MWHY-E> #DDVEP !ZDF/ 'N:JA@<X(.#@X.<'T/H?8U_H@G2-*((.F:>0000;
M*VP0>"#^ZZ$<&OSV_;K_ &!/A5^TM\+?%.H^'/!N@>&OC=H.CWFK>!_&.A:9
M::3?:MJ>G6[W,7A?Q,UA#"NM:/KJQ'34>_2>YT>YFM]1T^6/R)[:[_"^'?I<
M9/F6;X+ 9YPGB,DP.+KTL//-*.<PS*.#=::IQKXG#3RW 2^K4Y24Z]2E6G4I
MTE*4*-:45"7]8\9_LY>),DX=S/-N%/$/"<4YME^$KXRCD.*X9JY)4S)8>G*K
M+"X/&T\\S:"QM:,'3PM*MAZ=&M7E"G4Q-",G47\9%%.971F21'BD1F22.0%7
MCD0E7C=3RKHP*NIY# @\BFU_8%S_ #9::;35FG9I]&MT?NW_ ,$0_P!HR^\.
M?$SQ=^S5KM^[^'/B#IU]XV\#VTTA,>G^-O#UK$WB&SLU9@(U\0^&(3J%PJ@C
MS_#".BB2ZF9_Z=:_A _8[\93_#_]JO\ 9X\602/$-/\ B[X(M+HHVPOIFO:U
M;>'M6A+'@)/I>K7D+D\!7)(.,5_=_7^<OTJN&<-D_'^#SK"4XTH<3Y3#%8N,
M8J,99E@*KP>)JI*R3JX98&=1V3G6=6K)RG4DS_;#]GYQUCN)O!_,N&<QK3Q%
M;@3B&IEV G4DYRADF;8>.98+#N4KR:P^->:TZ2<G&GAE0HP484HQ7Y8?\%?O
M@?\ \+9_9&USQ9IUI]H\3?!/5[7XBV#1QL]P_AY5;2/&EHA4$B!-$O3KTX(P
MS>'H,D;0:_C^K_0Y\0:%I?BC0=;\,ZY:1W^B^(M(U+0M8L91F*\TO5[.;3]0
MM)!SF.XM+B:%QW5S7\#7QQ^%FJ_!#XP_$KX2:R)3>?#_ ,8ZUX=CGE4JU_IE
MK=,^B:JH(&8]7T673]3B8 !HKM"."*_6/HD<6_6\CS_@S$5;ULGQ<<XRZ$GJ
M\OS&U+&4J<>E/"XZE"M/3^)F6[Z?SO\ M&/#K^SN*>$/$W!4.7#\1X"IPWG=
M2$/=6;9,G7RRO6G;6MCLJKU,-35W^ZR7:-FY>5UIZ+K.I^'-9TCQ%HES)9:S
MH&JZ=K>D7D1*RVFJ:3>0ZAI]S&PZ/!=V\,JGU45F45_8$X1J0E3J1C.$XRA.
M$DI1G"2<91E%W4HR3:::LT[,_P VJ56I0JTZU&<Z=6C4A5I5(2E"=.I3DIPG
M"<6I1G"24HRBU*+2:::/[_\ X)?$W3/C-\(?AK\5M(,?V'Q_X+\/^)Q%&=RV
MEUJ>G03ZAIS')Q+INH&ZT^=224FMI%/(->HU^+O_  1'^,O_  FG[.7BKX1Z
MA=>;J_P;\93G3H9)@T@\'^.S<Z[IGEQM\XCM_$,'BJ E<QQQFV0;,A3^T5?X
M]>(/#,^#N->)>&W&4:>5YKB*>$YK\T\OK-8K+:CWUJX"OAJCU>LGJS_I2\'.
M.:?B3X7<#\;1G"I6S[A_!5\Q]G\%/.<-%X'.Z,;)65#-\+C:,;I/E@M%L9.O
MZYIGAC0M:\2:U<I9:-X>TG4=<U:\DXCM-,TFSFO[^Y<D@!(+6WEE;) PAY%?
MP&_&+XD:E\8?BO\ $?XJ:NSF_P#B#XT\0^*Y(W.3:V^KZE/<V%@H'"Q:=I[6
MMA"B_+'#;(B_*HK^MK_@K/\ &/\ X5-^QIXZTZRN_LVO_%F]TWX6:1Y<A2<V
MFOF:]\52(JG<8O\ A$M,UJSD885'OH Q!=0W\;M?V']$7A?ZMD?$G%]>G:KF
MN-I9-@927O+!Y;!8C%U*;MK3Q&+Q5*E+7^)@+65M?\U?VC?'OU[BG@GPXPE:
M]'(<LQ/$V;0A*\)9CG53ZGEU&M'I6P>7X&MB(;?NLV3UYO=***V_#/AS6/&/
MB3P]X1\/6KWNO^*M<TGPWHEF@)>ZU;7+^WTS3H  "?WMW=0H< X!)[5_8-2I
M"E3G5JSC3I4H2J5*DVHPA"$7*<Y2=E&,8IRDV[))MG^;%"A6Q->CAL/3G6KX
MBK3H4*5.,IU*M:K-4Z=.$(IRE.<Y1C&,4W*322;9_3I_P0^^!W_")_!+QS\<
M]5LS'J_Q9\2_V%X>GEC(<>"O TEQ9--;N<8BU3Q5=:XDX7Y91HMDY)"KC]P:
M\Q^"WPQT?X+?"7X<_"C05C_LSP!X0T/PS%-&I07MQIMC%%J&IR @'S]5U#[5
MJ5RQ +W%U*Y +$5Z=7^/WB)Q34XTXVXCXEE*3I9EF55X*,[\U/+<,HX3+:33
MVE# T,.II))U.>5KMG_29X,< T?##PNX*X'IPA&ODF1X:.9RII<M;.\9S8_.
MZZ<;\T:N:XK%RIMN35+V<>9J*"OY\/\ @NI\</LFA_"3]G?2KS$^M7ES\4_&
M-O&V&&F:5]JT#P?;3[3EHKW4Y_$-^T3X FT6RFP2$(_H/)QR> .23VK^&K]N
M_P"-W_#07[5OQ>^(-K=F[\/1^(I/"'@UPV8?^$2\& Z!I5Q;@%E6+5WM+O7R
M%8@S:M*V<M7ZW]&#A/\ U@\18YQ7I<^!X3P53,Y.2O!YEB>;!Y93EVG%SQ6-
MI/2T\"GY'\Z_3R\1/]3O!:IPWA*_LLU\0\THY%3C&7+6CDN!<,RSRO#76G)4
M\#E==6=Z6:M:7YE\B4445_I2?X<!7]07_!#GXWCQ-\'OB%\"-4O ^J?"_P 2
M+XI\-02R,9&\'>.&FEO+>W0D@PZ5XKL]3N)RNWRV\16JD'<IK^7VOOO_ ()E
M_'#_ (49^V%\,M3OKO[)X9^(%S+\*_%1>416XL?&<MM;:-=7+,PC6'3O%MOX
M?OII'_U=K%<D$;B:_)?'#A/_ %Q\->(L!2I>TQ^7X?\ MS+$E>?US*5+$2IT
MUUJ8K!_6\%!::XG<_HOZ*?B)_P 0U\<>#,WQ%=4,ISC&?ZJ9[*4G"DLMX@E3
MP<:U>5]*. S'ZAF<]],%LS^U6BBBO\H3_H5"N0^(/_(A>-_^Q0\2_P#IFO:Z
M^N0^(/\ R(7C?_L4/$O_ *9KVNG!_P"^83_L)H?^G8G%F7_(NQ__ &!8K_TQ
M4/\ /;C_ -7'_N+_ .@BGTR/_5Q_[B_^@BGU_M>?\MKW?J_S%569@JJS,Q 5
M5!9F)X 51DDD\  9)Z58^Q7O_/E>_P#@)<?_ !JOH#]D-5?]JS]FQ'1'1OCG
M\+U=)$5T=3XPTD,KHX*LK#(96!!!P017]V_]DZ5_T#-/_P# *V_^-U^!^,'C
MA_Q"G,LGR_\ U:_MW^UL#7QOM?[7_LWV'L<0J'L^3^S<=[3F^+GYX6VY7N?U
M]]&WZ*B^D'D7$F=/CE\*?ZOYMA<L^K?ZN?VU];^LX3ZU[;VO]MY5['D^#V?L
MZO-\7.OA/\\*6*6W -Q#- &X4SQ20ACZ*9%4$\C@9ZTRO]"K6O!?@[Q)I]QI
M/B+PGX:U[2KN-H;K3-:T+2]4T^YA?&^*XL[ZUGMYHWP-R21LK8&0<"OY2/\
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M"/\ F_XD_1&\6.#?$>? O#7#N<\<X/'4EF'#^?Y3EU2."Q65SJ.ESYKB92>
MR7%X.M_L^.IXW&4J,)NC6I59X?%8:=3\N#C!SC&#G/3'?.>,8ZU_5W_P2)_:
MC\4_$']GF]\!?$;2O&>H3?!Z^TOP[X3\;)X9\2:U8>)/!NHP7[:-I U2PTV\
MANM4\&'2[G1KG]\6CT63PXLF9_/=_2_V?_\ @D5^RC\&39:MXMT:]^./B^V,
M<O\ :OQ%6"3PY!<QLK^9IW@6RVZ$(]R@JFNGQ%-'D[;G/-?I_IVG:?I%C:Z9
MI-A9Z7IMC"EM9:?IUK!96-G;QC$<%K:6R16]O#&.$BAC1%'"J!7\V>./CIP3
MQ]DW^K.49!C\SAA\=1QF%XAQ=2&5RPE:C+EJ3R_#2HXK$U:6+PTJN'JK&1P=
MHU%-X>52E2G#^X?HJ?1.\4O"#B7_ %YXBXPRG)*F,RO$Y;CN#LNH5<]IYAA\
M3&,Z5/.,;'$X#!4*^ QE.CC,/++9YC>=+V:QD*-?$4I_Y^?Q,_Y*'XV_[&C6
M_P#TX3UP]=Q\3/\ DH?C;_L:-;_].$]</7]ZX'_<L'_V"X?_ --0/\C<_P#^
M1[G7_8VS'_U,K%FR_P"/VS_Z^[;_ -'QU_H;:/\ \@G2_P#L'67_ *315_GB
M0R&&:*8 ,8I8Y0ISAC&ZN <<X.W!Q7[J6_\ P7<^+UM;P6Z? +X:[+>&*!/^
M*J\4_=B18UZVS'HHZLQ]68\G^;/I'>&?%_B*N#UPK@*&._LAY[]>]MC\'@?9
M?7O['6&Y?K=:C[3G^J5^;V?-R*"YK<T;_P!N_0E\<_#CP8_XB1_Q$#.,3E7^
ML7^JG]E+#Y5F.9^W_LO_ %B^N\_U##8CV/L_[0PMO:\GM/:/DYN2=OZ>*^7?
MVU/BCX<^#_[+/QP\8^);JW@A;X>^)?#FCVLTJ1R:QXF\5Z5=>'O#VCVJ,=\\
M][J>H0>9'"LCQ6<=W=NH@MII$_"N7_@O#\9FBD6#X"_#&*8J1%)+XD\57$2/
M_"TD"1VSRJ#U1;B$MVD7K7YI_M0_MH_'C]KG5["\^*_B&T30-$GEN/#O@3PQ
M:2Z1X-T.XF62-[Z+3Y+F\O-2U5H)'M_[7UJ_U&_BMWDMK66VMI9(&_#^!_HP
M\>3XDRO$<54L!D^2X'&8;&8V4,QPV.Q>+I8>K"L\'A*>"G6C"IB.7V4JU>I2
MA0A*56*K3A&C4_JKQ6^GAX24>"<^P? &)S;B7BC-<LQN6Y73J9-C,LR[+\1C
M<//#K,,QKYG3P\ZE'"*HZ\,-A:.(J8JK3AAYRP].I/$4OD]%VHJ]=JJN?7
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M?E'C#P2B"QN;A@H"R:KX5O+*U@#$EU\-3D'Y2*_J&KX%_P""F7P./QV_8_\
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MY$5IJ,/AR_6),CS=7O9L ER?Z$Z_R*\5N%'P5Q_Q+D$*;IX.AF$\5EBM[O\
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M4%S&V'ANET3[5 X#P31L,U]\#C@# '  [5_*/_P_&_:R_P"A&^!?_A.>-/\
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MW]I3_LH]S_Z:-)KXRK[-_P""B'_)[O[2G_91[G_TT:37QE7^NW O_)$<'?\
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M7_9F!JT-5S5, \14S-Q35Z6!JOH?SV\]R6/=F)+,>[,3R68\DGDDDFBBBO\
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M/.#^.,(Z?)Q)D6!S"O3I:PPV8NG['-<$G=ZX',Z.+P<M7[U!ZL_EB_X+J?\
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MQ\3/^2A^-O\ L:-;_P#3A/7#USX'_<L'_P!@N'_]-0/1S_\ Y'N=?]C;,?\
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M/Z_G7K^BC_@O?]W]E_\ ZZ?%K_T7\/Z_G7K_ %)^CE_R9SA'USW_ -:3-S_
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MA%RNXQ<YN*:3E*UW_&/_ ,.G/V]/^B*6_P#X<7X;?_-77"_$S_@G-^V)\'_
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MG9-G\^U(0""",@@@CU!X(I:*_P!$3_%VY_8U_P $J?VHC^T3^S7IGA_Q%?\
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M/L1CL1['&YIAZ<\5CH4L9BZRHT,;3HTW7Q5:K6E&G3A!2J2Y8I.P?\._)?\
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M_FGS>@_ZGFG?\._)?^BNQ_\ AOF_^;FBBOZ>_P!>.*?^AI_Y99=_\R'\)?\
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FZ-7!X/&UJ^78+$TISE*&*PF#HXF+::J^[&WZ(T445_))_HL?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
